Biotech/ Pharma Stocks Articles, Commentary and Sector Alerts
Investment Banker Dick Huebner on How to Uncover Micro-Cap Biotechs that Deliver on Promises
November 21, 2014 (Investorideas.com Newswire) Micro-cap stocks suffer from all sorts of ills. They are often illiquid, and companies can be unable to raise new funds under reasonable terms, if at all.
Breaking Pharma Stock News: Actavis (ACT) to Acquire Allergan (AGN) to Create Top 10 Global Growth Pharmaceutical Company with $23 Billion in Revenue
DUBLIN and IRVINE, Calif. - November 17, 2014 (Investorideas.com Newswire) Actavis plc (ACT) and Allergan, Inc. (AGN) today announced that they have entered into a definitive agreement under which Actavis will acquire Allergan for a combination of $129.22 in cash and 0.3683 Actavis shares for each share of Allergan common stock.
R. Lee Buckler: How RepliCel Is Harnessing the Awesome Power of Cell Therapy
November 7, 2014 (Investorideas.com Newswire) Regenerative medicine and cell therapies hold possibilities for achieving near miracles in a multitude of indications, from life-saving treatments to aesthetic applications.
A Tour of Australian Biotechs with Morgans' Scott Power
October 2, 2014 (Investorideas.com Newswire) Australia is a powerhouse for medical science innovations, and nobody understands that better than Scott Power of Morgans Financial Ltd.
Wedbush Securities' Liana Moussatos on the Art and Science of Picking Biotechs with Upside
August 21, 2014 (Investorideas.com Newswire) Liana Moussatos of Wedbush Securities doesn't wait for the catalyst to strike. She, like other successful investors, picks her targets and takes profits earlier, while less sophisticated investors wait for the press releases.
Biotech Stock Directory Update
New York, NY - Point Roberts, WA - August 14, 2014 (Investorideas.com Newswire) Investorideas.com staff: Investorideas.com, a global news source covering leading sectors issues the updated biotech stock directory for August.
Pharma Stock CASI Pharmaceuticals (CASI) Receives U.S. Orphan Drug Designation For The Use Of ENMD-2076 To Treat Hepatocellular Carcinoma
ROCKVILLE, MD - July 9, 2014 (Investorideas.com Newswire) CASI Pharmaceuticals, Inc. (CASI), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, announced today that its orally-active, Aurora A/angiogenic kinase inhibitor, ENMD-2076, has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of hepatocellular carcinoma (HCC).
Fire Up the Immuno-Oncology Powerhouses: John McCamant
June 19, 2014 (Investorideas.com Newswire) Forecasting when we'll have a cure for cancer remains beyond the predictive powers of researchers and investors.
Medical Technology News: Medical Technology The Role of Aethlon Medical (OTCQB: AEMD) in the Emerging Immuno-Oncology Market; Q&A with Aethlon Chairman and CEO, Jim Joyce
Point Roberts, WA, NEW YORK, NY - June 10, 2014 (Investorideas.com newswire) Investorideas.com, a global news source covering leading sectors including biotech and medical technology issues a Q&A interview with Mr. James A. Joyce ,Chairman and CEO of Aethlon Medical, Inc. (OTCBB:AEMD).
ASCO Abuzz About Immunotherapies: A Preview of the Latest in Cancer Therapy from Stephen Dunn
May 29, 2014 (Investorideas.com Newswire) Working in what is arguably the hottest sector in the drug development industry, biotech researchers continue to ferret out cancer's secrets.
Turn Solid Gold into Biotech Gold with James West
May 29, 2014 (Investorideas.com Newswire) The globe-trotting editor and publisher of The Midas Letter has decided to give his metal investments a breather, looking for new prospects in the life sciences space.
Harnessing the Power of Nature's Perfect Cells: Robert J. Hariri
May 23, 2014 (Investorideas.com Newswire) Neurosurgeon and serial entrepreneur Robert J. Hariri, founder, chairman and chief science officer at Celgene Cellular Therapeutics, describes how his businesses address some of the great unmet needs in medicine in this interview with The Life Sciences Report.
Live Longer, Get Richer with Patrick Cox
May 8, 2014 (www.investorideas.com newswire) It's what every biotech investor dreams of: Transformational advances in healthcare technologies that allow us to live for centuries and accumulate wealth exponentially.
X-Ray Vision or Due Diligence? How SeeThruEquity Analysts Find Hidden Small-Cap Biotech Plays
May 2, 2014 (Investorideas.com Newswire) SeeThruEquity stays an arm's length away from the small biotech firms it analyzes for investors, but gets intimate enough to discover firms that hold promise.
New Melanoma Therapies Are Ready for Primetime: Sanjiv Agarwala
April 30, 2014 (Investorideas.com Newswire) Melanoma confronts patients and their physicians with unique barriers to treatment and successful outcomes.
Do the Math: Ram Selvaraju on the Appeal of Biotechs in Orphan Diseases
April 22, 2014 (Investorideas.com Newswire) To cast a spotlight on disruptive biotechnology stocks, Raghuram "Ram" Selvaraju of Aegis Capital Corp. taps his experience as a molecular biologist, preclinical investigator and sellside analyst.
TSX Biotech Stocks to Watch; Innovative Ovarian Cancer Treatments
New York, NY - Point Roberts, WA - March 26, 2014 (Investorideas.com Newswire) Investorideas.com, a global news source for leading sectors including biotech and pharma issues a sector snapshot of TSX biotech stocks targeting ovarian cancer as part of their product pipeline.
Biopharma IPO alert: Versartis, Inc., (Nasdaq:VSAR) Soars
New York, NY - Point Roberts, WA - March 21, 2014 (Investorideas.com Newswire) Investorideas.com, a global financial and business news source covering leading sectors including biotech issues an IPO alert for Versartis, Inc., (Nasdaq:VSAR) an endocrine-focused biopharmaceutical company.
IPO Alert: Akebia Therapeutics, Inc. (AKBA) Surges in NASDAQ Market Debut
New York, NY - Point Roberts, WA - March 20, 2014 (Investorideas.com Newswire) Investorideas.com, a global financial and business news source covering leading sectors including biotech, issues an IPO alert on Akebia Therapeutics, Inc. (AKBA).
Promising Biotechs Target New Ways to Kill Bad Bugs: Venture Capitalist Dennis Purcell
March 18, 2014 (Investorideas.com Newswire) Dennis Purcell, senior managing partner of Aisling Capital, has seen the biotechnology industry morph from exciting science project to a full-blown, multibillion-dollar industry producing blockbuster products that routinely save lives.